Browse > Article
http://dx.doi.org/10.3857/jkstro.2009.27.2.84

Concurrent Chemoradiotherapy in Elderly Patients with Locally Advanced Esophageal Carcinoma  

Jung, Bae-Kwon (Departments of Radiation Oncology, School of Medicine, Gyeongsang National University)
Kang, Ki-Mun (Departments of Radiation Oncology, School of Medicine, Gyeongsang National University)
Lee, Gyeong-Won (Internal Medicine, School of Medicine, Gyeongsang National University)
Kang, Jung-Hoon (Internal Medicine, School of Medicine, Gyeongsang National University)
Kim, Hoon-Gu (Internal Medicine, School of Medicine, Gyeongsang National University)
Lee, Won-Seob (Internal Medicine, School of Medicine, Gyeongsang National University)
Chai, Gyu-Young (Departments of Radiation Oncology, School of Medicine, Gyeongsang National University)
Publication Information
Radiation Oncology Journal / v.27, no.2, 2009 , pp. 84-90 More about this Journal
Abstract
Purpose: The effect of concurrent chemoradiotherapy was analyzed in elderly patients when used in the treatment of locally advanced esophageal cancer. Materials and Methods: The retrospective analysis included 28 elderly patients aged 65 or older, with histopathologically confirmed squamous cell carcinoma of the esophagus, underwent concurrent chemoradiotherapy from January 2001 to July 2007. The squamous cell carcinoma disease stages included 8 patients (28.8%) in stage IIa, 10 patients (35.7%) in stage IIb, and 10 patients (35.7%) in stage III. Fractionated radiotherapy was performed with a 6 MV or 10 MV X-ray for 45~63 Gy (median: 59.4 Gy). Chemotherapy was applied concurrently with the initiation of radiotherapy. A 75 mg/$m^2$ dose of Cisplatin was intravenously administered on day 1. Further, 5-FU 1,000 mg/$m^2$ was continuously administered intravenously from days 1 to 4. This regimen was performed twice at 3-week intervals during radiotherapy. Two cycles of consolidation chemotherapy was performed after radiotherapy. Results: The follow-up period was 3~72 months (median: 19 months). The treatment responses after concurrent chemoradiotherapy included a complete response in 11 patients (39.3%), a partial response in 14 patients (50.0%), and no response in 3 patients (10.7%). The overall response rate was 89.3% (25 patients). The overall 1-, 2- and 3-year survival rates were 55.9%, 34.6% and 24.2%, respectively. The median survival time was 15 months. Two-year survival rates of patients with a complete response, partial response, and no response were 46.2%, 33.0%, and 0%, respectively. The stage and tumor response after concurrent chemoradiotherapy were statistically significant prognostic factors related with survival. No treatment-related deaths occurred in this study. Conclusion: Concurrent chemoradiotherapy is a relatively effective treatment without serious complications in elderly patients with locally-advanced esophageal cancer.
Keywords
Elderly patients; Esophageal carcinoma; Concurrent chemoradiotherapy;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Schattenkerk ME, Obertop H, Mud HJ, Eijkenboom WM, van Andel JG, van Houten H. Survival after resection for carcinoma of the oesophagus. Br J Surg 1987;74:165-168   DOI   ScienceOn
2 Petrovich Z, Langholz B, Formenti S, Luxton G, Astrahan M. Management of carcinoma of the esophagus: the role of radiotherapy. Am J Clin Oncol 1991;14:80-86   DOI   ScienceOn
3 James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-528   DOI   ScienceOn
4 Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481
5 Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110-4117   DOI   ScienceOn
6 Kelsen DP. Multimodality therapy of local regional esophageal cancer. Semin Oncol 2005;32:6-10
7 Noh OK, Je HU, Kim SB, et al. Results of definitive chemoradiotherapy for unresectable esophageal cancer. J Korean Soc Ther Radiol Oncol 2008;26:195-203   DOI   ScienceOn
8 Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310–2317   PUBMED
9 Takeuchi S, Ohtsu A, Doi T, et al. A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol 2007;30:607–611   PUBMED
10 Moskovitz AH, Rizk NP, Venkatraman E, et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2006;82:2031–2036   PUBMED
11 Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004;240:791–800   PUBMED
12 van Lanschot JJ, Aleman BM, Richel DJ. Esophageal carcinoma: surgery, radiotherapy, and chemotherapy. Curr Opin Gastroenterol 2002;18:490-495   DOI   ScienceOn
13 Nam TK, Nah BS, Chung WK, Ahn SJ, Song JY. Results of concurrent chemoradiotherapy and intraluminal brachytherapy in esophageal carcinoma - retrospective analysis with respect to survival. J Korean Soc Ther Radiol Oncol 2004;22:25-32
14 Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412–2418   PUBMED
15 Trumper M, Ross PJ, Cunningham D, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophagogastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 2006;42:827–834   PUBMED
16 Ruol A, Portale G, Castoro C, et al. Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg 2007;32:445–448   PUBMED
17 Cmelak AJ, Murphy BA, Day T. Combined-modality therapy for locoregionally advanced head and neck cancer. Oncology 1999;13:83-91
18 Hennequin C, Maylin C. Continuous radiosensitizing chemotherapy. Pathol Biol 1999;47:279-281   PUBMED
19 Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991;173:123-130   PUBMED
20 Semrau S, Bier A, Thierbach U, et al. 6-year experience of concurrent radiochemotherapy with vinorelbine plus a platinum compound in multimorbid or aged patients with inoperable nonsmall cell lung cancer. Strahlenther Onkol 2007;183:30–35   PUBMED
21 Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992–1994 patterns of care study. J Clin Oncol 2000;18: 455–462   PUBMED
22 Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160–1168   PUBMED
23 Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989;16:329-334   DOI   PUBMED   ScienceOn
24 Cox J, Stetz J, Pajak T. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–1346   PUBMED
25 Tougeron D, Di Fiore F, Hamidou H, Rigal O, Paillot B, Michel P. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma vs squamous cell carcinoma: a matchedpair analysis. Oncology 2008;73:328–334
26 Rich T. Chemoradiation in conservation therapy for esophageal cancer. Hematol Oncol Clin North Am 2001;15:291-302   DOI   PUBMED   ScienceOn
27 Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer 2007;96:1823–1827   PUBMED
28 Polee MB, Hop WCJ, Kok TC, et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003;89:2045–2050   PUBMED
29 Burtin P, Bouche O, Giovannini M, et al. Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Federation Francophone de Cancerologie Digestive. Gastroenterol Clin Biol 2008;32:213–220   PUBMED
30 Pasetto LM, Friso ML, Pucciarelli S, et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res 2006; 26:3913–3923   PUBMED
31 Minsky BD, Neuberg D, Kelsen DP, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999;43:517–523   PUBMED
32 Pisch J, Berson AM, Malamud S, Beattie EJ, Harvey J, Vikram B. Chemoradiation in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1995;33:183-188   DOI   PUBMED   ScienceOn